T1	Participants 65 122	postmenopausal patients with metastatic breast carcinoma:
T2	Participants 642 778	683 postmenopausal patients were randomized to receive either fadrozole HCL, 1 mg twice daily, or megestrol acetate, 40 mg 4 times daily
